NCCN Guidelines for Patients® | Non-Small Cell Lung Cancer - page 77

NCCN Guidelines for Patients
: Non-Small Cell Lung Cancer
Version 1.2014
Part 7: Treatment by cancer stage
Par t 1
Par t 2
Par t 3
Par t 4
Par t 5
Par t 6
Par t 7
Par t 8
Par t 9
histologic subtype:
type of cancer based on
the traits of the cells
An abnormal
change in the coded
instructions within cells
for creating new cells
and controlling how cells
Read page 71
for definitions of
performance scores.
During or after first-line treatment, the cancer may grow. The chart on page 76
lists treatment options that can be used after first-line treatments. Treatment
options are based on histologic subtypes and performance scores.
If your performance score is 0, 1, or 2, docetaxel, erlotinib, or gemcitabine is
recommended for any histologic subtype. Erlotinib can be given whether the
EGFR mutation is present or not. Pemetrexed is also listed for non-squamous
histologic subtypes.
Besides these cancer drugs, you may be treated with best supportive care.
Supportive care treats the symptoms caused by the cancer but not the cancer
itself. The last option for a performance score between 0 and 2 is joining a
clinical trial. A clinical trial is a type of research that studies how well a treatment
works. Because of clinical trials, the treatments in this booklet are now widely
used to help patients.
If your performance score is 3 or 4, most drugs for lung cancer are likely to
seriously harm your health. Thus, best supportive care is recommended.
Erlotinib can only be taken if the EGFR mutation is present. EGFR mutation is
very rare in squamous cell carcinoma.
1...,67,68,69,70,71,72,73,74,75,76 78,79,80,81,82,83,84,85,86,87,...108
Powered by FlippingBook